SGLT2 inhibitors in the treatment of type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 104, Issue 3, 2014, Pages 297-322

  Hasan, Farhad M ^a   Alsahli, Mazen ^b   Gerich, John E ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Canagliflozin; Dapagliflozin; Empagliflozin; Glucose reabsorption; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; PIOGLITAZONE; PLACEBO; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; SULFONYLUREA;

ADD ON THERAPY; BACKACHE; BALANITIS; BLADDER CANCER; BLOOD PRESSURE REGULATION; BODY WEIGHT DISORDER; BREAST CANCER; CARDIOVASCULAR DISEASE; DEHYDRATION; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FRACTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLUCOSURIA; GLYCOGENOLYSIS; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; KIDNEY; KIDNEY DYSFUNCTION; KIDNEY TUBULE ABSORPTION; MONOTHERAPY; MYCOSIS; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSMOTIC DIURESIS; POLLAKISURIA; POLYDIPSIA; POLYURIA; POSITIONAL DIZZINESS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VULVOVAGINITIS;

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE REABSORPTION; SGLT2 INHIBITORS; TYPE 2 DIABETES;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84902551594     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.02.014     Document Type: Review

References (142)

1. Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014:S5-13.
2. National Institute for Health and Clinical Excellence The management of type 2 diabetes: 2010 NICE guidelines [Internet] 2010, National Institute for Health and Clinical Excellence, London, U.K., Available from http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf [accessed 30.10.13].
3. Bennett W.L., Odelola O.A., Wilson L.M., Bolen S., Selvaraj S., Robinson K.A., et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med 2012, 1(Pt 1):27-36.
4. Bailey C., Krentz A. Oral antidiabetic agents. Textbook of diabetes 2010, Blackwell Publishing Ltd., Oxford. 4th ed. J. Pickup, G. Williams (Eds.).
5. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 23:2427-2443.
6. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 6:1364-1379.
7. Philippe J., Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents?. Int J Clin Pract 2009, 2:321-332.
8. Tahrani A.A., Bailey C.J., Del Prato S., Barnett A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 9786:182-197.
9. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 3:385-411.
10. Alsahli M., Gerich J. Hypoglycemia, chronic kidney disease and diabetes. Diabetic Hypoglycemia 2013, 6(September (2)):12-16.
11. Gerich J.E. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010, 2:136-142.
12. Gerich J.E. Physiology of glucose homeostasis. Diabetes Obes Metab 2000, 6:345-350.
13. Landau B.R., Wahren J., Chandramouli V., Schumann W.C., Ekberg K., Kalhan S.C. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996, 2:378-385.
14. Stumvoll M., Meyer C., Mitrakou A., Nadkarni V., Gerich J.E. Renal glucose production and utilization: new aspects in humans. Diabetologia 1997, 7:749-757.
15. Consoli A., Kennedy F., Miles J., Gerich J. Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man. J Clin Invest 1987, 5:1303-1310.
16. Meyer C., Dostou J.M., Welle S.L., Gerich J.E. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002, 2:E419-E427.
17. Meyer C., Dostou J.M., Gerich J.E. Role of the human kidney in glucose counterregulation. Diabetes 1999, 5:943-948.
18. Gerich J.E. Hepatorenal glucose reciprocity in physiologic and pathologic conditions. Diabetes Nutr Metab 2002, 5:298-302. [discussion 302-3].
19. Cersosimo E., Garlick P., Ferretti J. Renal glucose production during insulin-induced hypoglycemia in humans. Diabetes 1999, 2:261-266.
20. Stumvoll M., Meyer C., Kreider M., Perriello G., Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 1998, 10:1227-1232.
21. Meyer C., Stumvoll M., Welle S., Woerle H.J., Haymond M., Gerich J. Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans. Am J Physiol Endocrinol Metab 2003, 4:E819-E826.
22. Stumvoll M., Chintalapudi U., Perriello G., Welle S., Gutierrez O., Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 1995, 5:2528-2533.
23. Wright E.M., Hirayama B.A., Loo D.F. Active sugar transport in health and disease. J Intern Med 2007, 1:32-43.
24. Lee Y.J., Lee Y.J., Han H.J. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007, 106:S27-S35.
25. Chen J., Feder J., Neuhaus I., Whaley J. Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: implication for targeting SGLT2 in type 2 diabetes patients (2493-PO). Diabetes 2008, 57:A682.
26. Wright E.M. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001, 1:F10-F18.
27. Brown G.K. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 2000, 3:237-246.
28. Bakris G.L., Fonseca V.A., Sharma K., Wright E.M. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009, 12:1272-1277.
29. Silverman M., Turner J. Glucose transport in the renal proximal tubule. Handbook of physiology 1992, 2017-2038. Oxford University Press, New York, Copyright © 1992 by the American Physiological Society. By permission of Oxford University Press Inc. E.E. Windhager (Ed.).
30. Zelikovic I. Aminoaciduria and glycosuria. Pediatric nephrology 2004, 701-728. Lippincott Williams & Wilkins, Philadelphia. 5th ed. E.D. Avner, W.E. Harmon, P. Niaudet (Eds.).
31. Santer R., Kinner M., Lassen C.L., Schneppenheim R., Eggert P., Bald M., et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003, 11:2873-2882.
32. Meyer C., Stumvoll M., Nadkarni V., Dostou J., Mitrakou A., Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998, 3:619-624.
33. Meyer C., Woerle H.J., Dostou J.M., Welle S.L., Gerich J.E. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 2004, 6:E1049-E1056.
34. Mogensen C.E. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971, 1:101-109.
35. Farber S.J., Berger E.Y., Earle D.P. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951, 2:125-129.
36. Rahmoune H., Thompson P.W., Ward J.M., Smith C.D., Hong G., Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 12:3427-3434.
37. Vestri S., Okamoto M.M., de Freitas H.S., Aparecida Dos Santos R., Nunes M.T., Morimatsu M., et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001, 2:105-112.
38. Ehrenkranz J.R., Lewis N.G., Kahn C.R., Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005, 1:31-38.
39. Rossetti L., Smith D., Shulman G.I., Papachristou D., DeFronzo R.A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 5:1510-1515.
40. Wright E.M.I. Glucose galactose malabsorption. Am. J. Physiol. 1998, 5(Pt 1):G879-G882.
41. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007, 4:285-292.
42. Tahrani A.A., Barnett A.H., Bailey C.J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013, 2:140-151.
43. Fujimori Y., Katsuno K., Nakashima I., Ishikawa-Takemura Y., Fujikura H., Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008, 1:268-276.
44. Fujimori Y., Katsuno K., Ojima K., Nakashima I., Nakano S., Ishikawa-Takemura Y., et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009, 1-3:148-154.
45. Washburn W.N. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009, 7:1785-1794.
46. Dobbins R.L., O'Connor-Semmes R., Kapur A., Kapitza C., Golor G., Mikoshiba I., et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012, 1:15-22.
47. Hussey E.K., Kapur A., O'Connor-Semmes R.L., Tao W., Poo J.L., Dobbins R.L. Safety, pharmacokinetics and pharmacodynamics of Remogliflozin etabonate (SGLT2 Inhibitor) and metformin when co-administered in type 2 diabetes mellitus (T2DM) patients. Diabetes 2010, 59(Suppl. 1). [abstract 564-P, 2009:A157].
48. Hussey E.K., Clark R.V., Amin D.M., Kipnes M.S., O'Connor-Semmes R.L., O'Driscoll E.C., et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010, 6:623-635.
49. Obermeier M., Yao M., Khanna A., Koplowitz B., Zhu M., Li W., et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010, 3:405-414.
50. Bellamine A., Smarsh M., Onorato J., Dapagliflozin (BMS-512148) is a competitive, selective and reversible inhibitor of human SGLT2. Presented at: biomedical transporters conference 2009.
51. Han S., Hagan D.L., Taylor J.R., Xin L., Meng W., Biller S.A., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 6:1723-1729.
52. Komoroski B., Vachharajani N., Feng Y., Li L., Kornhauser D., Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 5:513-519.
53. List J.F., Woo V., Morales E., Tang W., Fiedorek F.T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 4:650-657.
54. Sjöström D., Sugg J., Ptaszynska A., Parikh S. Presentation at the European Society of Cardiology 2014, Available at: http://spo.escardio.org/eslides/view.aspx?eevtid=54&fp=3972 [accessed January 10].
55. Janssen Research and Development, LLC. Canagliflozin slides presented at the Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, January 10, 2013. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm336233.htm [accessed 11.01.14].
56. Ferrannini E., Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012, 8:495-502.
57. Thomson S.C., Vallon V., Blantz R.C. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004, 1:F8-F15.
58. Liu J.J., Lee T., DeFronzo R.A. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?. Diabetes 2012, 9:2199-2204.
59. Komoroski B., Vachharajani N., Boulton D., Kornhauser D., Geraldes M., Li L., et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 5:520-526.
60. FDA approves dapagliflozin. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm [accessed 10.01.14].
61. European Medicines Agency authorizing the use of dapagliflozin in November 2012. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001d124 [accessed 10.01.13].
62. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013, 5:432-440.
63. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 10:2217-2224.
64. Ji L., Ma J., Li H., Mansfield T.A., T'joen C.L., Iqbal N., et al. Dapagliflozin as monotherapy in drug-naive asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 2013, 36(1):84-100.
65. Henry R.R., Murray A.V., Marmolejo M.H., Hennicken D., Ptaszynska A., List J.F. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012, 5:446-456.
66. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 9733:2223-2233.
67. Bolinder J., Ljunggren O., Kullberg J., Johansson L., Wilding J., Langkilde A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 3:1020-1031.
68. Nauck M.A., Del Prato S., Meier J.J., Duran-Garcia S., Rohwedder K., Elze M., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011, 9:2015-2022.
69. Strojek K., Yoon K.H., Hruba V., Elze M., Langkilde A.M., Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes. Metab 2011, 10:928-938.
70. Rosenstock J., Vico M., Wei L., Salsali A., List J.F. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012, 7:1473-1478.
71. Jabbour S.A., Hardy E., Sugg J., Parikh S. Dapagliflozin Is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled studys. Diabetes Care 2013, for the Study 10 Group, DC_130467.
72. Wilding J.P., Norwood P., T'joen C., Bastien A., List J.F., Fiedorek F.T. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 9:1656-1662.
73. Wilding J.P., Woo V., Soler N.G., Pahor A., Sugg J., Rohwedder K., et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012, 6:405-415.
74. Wilding J.P., Woo V., Rohwedder K., Sugg J., Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2013, 16(2):124-136. for the Dapagliflozin 006 Study Group.
75. Ptaszynska A., Hardy E., Johnsson E., Parikh S., List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 2013, 3:181-189.
76. Johnsson K.M., Ptaszynska A., Schmitz B., Sugg J., Parikh S.J., List J.F. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013, 5:479-484.
77. Johnsson K.M., Ptaszynska A., Schmitz B., Sugg J., Parikh S.J., List J.F. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013, 5:473-478.
78. Leiter L., Cefalu W., de Bruin T., Gause-Nilsson I., Sugg J., Parikh S. Efficacy and safety of dapagliflozin for type 2 diabetes mellitus patients with a history of cardiovascular disease. 72nd American Diabetes Association Scientific Sessions 2012.
79. FORXIGA®. Summary of product characteristics. Bristol-Myers Squibb/AstraZeneca EEIG; 2013.
80. Burki T.K. FDA rejects novel diabetes drug over safety fears. Lancet 2012, 9815:507.
81. Ptaszynska A., Johnsson K., Apanovitch A.M., Sugg J., Parikh S., List J. Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus. Int Med J 2013, 43:p50.
82. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011, 9:645-646.
83. Kohan D., Fioretto P., List J. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract no. TH-PO524]. J Am Soc Nephrol 2011, 232A.
84. FDA news release approving Invokana in March 29, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm [accessed 11.01.14].
85. European Commission approving Invokana on November 22, 2013. Available at: http://ec.europa.eu/health/documents/community-register/html/newproc.htm#h [accessed 11.01.14].
86. Stenlof K., Cefalu W.T., Kim K.A., Alba M., Usiskin K., Tong C., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 4:372-382.
87. Inagaki N., Kondo K., Yoshinari T., Maruyama N., Susuta Y., Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013, 12:1136-1145.
88. Rosenstock J., Aggarwal N., Polidori D., Zhao Y., Arbit D., Usiskin K., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012, 6:1232-1238.
89. Lavalle-Gonzalez F.J., Januszewicz A., Davidson J., Tong C., Qiu R., Canovatchel W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013, 12:2582-2592.
90. Cefalu W.T., Leiter L.A., Yoon K.H., Arias P., Niskanen L., Xie J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 9896:941-950.
91. Wilding J.P., Charpentier G., Hollander P., Gonzalez-Galvez G., Mathieu C., Vercruysse F., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013, 12:1267-1282.
92. Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013, 9:2508-2515.
93. Forst T., Guthrie R., Goldenberg R., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes on metformin and pioglitazone [abstract]. 4th world congress on controversies to consensus in diabetes, obesity, and hypertension 2012.
94. Matthews D, Fulcher G, Perkovic V, de Zeeuw D, Mahaffey K, Rosenstock J, et al. Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D). Diabetologie und Stoffwechsel S01:P251, 2012.
95. Yale J.F., Bakris G., Cariou B., Yue D., David-Neto E., Xi L., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 5:463-473.
96. Bode B., Stenlof K., Sullivan D., Fung A., Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) 2013, 2:72-84.
97. Polidori D., Sha S., Mudaliar S., Ciaraldi T.P., Ghosh A., Vaccaro N., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion results of a randomized, placebo-controlled study. Diabetes Care 2013, 36(8):2154-2161.
98. Baigent C., Keech A., Kearney P.M., et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
99. INVOKANA® [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2013. Available at: http://www.invokanahcp.com/prescribing-information.pdf [accessed 11.01.14].
100. Nyirjesy P., Zhao Y., Ways K., Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012, 7:1173-1178.
101. Nicolle L., Capuano G., Ways K., Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012, 7:1167-1171.
102. Kawalec P., Mikrut A., Łopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res 2013.
103. Janssen Research & Development, LLC. CANVAS - CANagliflozin cardioVascular Assessment Study. NLM identifier: NCT01032629. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01032629 [accessed 12.01.14].
104. Tucker M.E. Experts welcome canagliflozin approval, but questions remain. Heart Org 2014, Available at: http://www.theheart.org/article/1530799.do [accessed January 11].
105. Matthews D.R., Fulcher G., Perkovic V., et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes [abstract]. 48th European Association for the Study of Diabetes. Annual meeting 2012.
106. Lamos E.M., Younk L.M., Davis S.N. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013, 6:763-775.
107. Daousi C., Casson I.F., Gill G.V., MacFarlane I.A., Wilding J.P., Pinkney J.H. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006, 966:280-284.
108. Nair S., Joseph F., Ewins D., Wilding J., Goenka N. From history to reality: sodium glucose co-transporter 2 inhibitors-a novel therapy for type 2 diabetes mellitus. Pract Diabetes Int 2010, 7:311-316.
109. Clinical development pipline on Lilly's website. Available at: http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical Development Pipeline/13.html [accessed 14.01.14].
110. Grempler R., Thomas L., Eckhardt M., Himmelsbach F., Sauer A., Sharp D., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 1:83-90.
111. Seman L., Macha S., Nehmiz G., Simons G., Ren B., Pinnetti S., et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2013, 2(2):152-161.
112. Heise T., Seewaldt-Becker E., Macha S., Hantel S., Pinnetti S., Seman L., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013, 7:613-621.
113. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin. Available at: https://investor.lilly.com/releasedetail.cfm?ReleaseID=750602 [accessed 14.01.14].
114. Ferrannini E., Seman L., Seewaldt-Becker E., Hantel S., Pinnetti S., Woerle H.J. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013, 8:721-728.
115. Roden M., Weng J., Eilbracht J., Delafont B., Kim G., Woerle H.J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013, 3:208-219.
116. Haring H.U., Merker L., Seewaldt-Becker E. Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes(T2DM). Diabetes 2013, 62(suppl 1):A282.
117. Rosenstock J., Seman L.J., Jelaska A., Hantel S., Pinnetti S., Hach T., et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013, 12:1154-1160.
118. Haring H.U., Merker L., Seewaldt-Becker E., Weimer M., Meinicke T., Woerle H.J., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013, 11:3396-3404.
119. Kovacs C.S., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H.J., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014, 16(2):147-158.
120. Rosenstock J., Jelaska A., Kim G., Broedl U., Woerle H. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Diabetes 2013, 62(Suppl. 1):A285. [Asbtract 1102-P].
121. Woerle H., Ferrannini E., Berk A., Manun'Ebo M., Pinnetti S., Broedl U. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes. 72nd scientific sessions of the American Diabetes Association 2012.
122. Hach T., Heerspink H.J.L., Pfarr E., Lund S., Ley L., Broedl U.C., et al. The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c change. Presented at the 48th European Association for the Study of Diabetes (EASD) annual meeting 2012, 1-5.
123. Ferrannini E., Berk A., Hantel S., Pinnetti S., Hach T., Woerle H.J., et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013, 12:4015-4021.
124. Macha S., Mattheus M., Halabi A., Pinnetti S., Woerle H.J., Broedl U.C. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014, 16:215-222.
125. Macha S., Rose P., Mattheus M., Cinca R., Pinnetti S., Broedl U.C., et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2014, 16:118-123.
126. Ridderstrale M., Svaerd R., Zeller C., Kim G., Woerle H.J., Broedl U.C., et al. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 2013, 129-2840-12-129.
127. Astellas submits application for approval of ipragliflozin in Japan [March, 2013]. Available at: http://www.astellas.com/en/corporate/news/pdf/130313_1_Eg.pdf [accessed 16.01.14].
128. Ipragliflozin approved in Japan in January 2014. Available at: http://www.astellas.com/en/corporate/news/detail/approval-of-suglat-tablets-a-s.html [accessed 25.01.14].
129. Veltkamp S.A., Kadokura T., Krauwinkel W.J., Smulders R.A. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011, 12:839-851.
130. Schwartz S.L., Akinlade B., Klasen S., Kowalski D., Zhang W., Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011, 12:1219-1227.
131. Smulders R.A., Zhang W., Veltkamp S.A., van Dijk J., Krauwinkel W.J., Keirns J., et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab 2012, 10:937-943.
132. Kashiwagi A., Takinami Y., Kazuta K., Yoshida S., Utsuno A., Nagase I. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study 2011, S68-S69.
133. Fonseca V.A., Ferrannini E., Wilding J.P., Wilpshaar W., Dhanjal P., Ball G., et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 2013, 3:268-273.
134. Goto K., Kashiwagi A., Kazuta K. Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study. Diabetes 2012, Suppl. 1:A269.
135. Wilding J.P., Ferrannini E., Fonseca V.A., Wilpshaar W., Dhanjal P., Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013, 5:403-409.
136. Kashiwagi A., Shiga T., Akiyama N. Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone. Presented at the 48th EASD annual meeting 2012, [Poster 739].
137. LX4211 in the pipeline by Lexicon Pharmaceuticals. Available at: http://www.lexgen.com/pipeline/lx4211.html [accessed 16.01.14].
138. Zambrowicz B., Freiman J., Brown P., Frazier K., Turnage A., Bronner J., et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012, 2:158-169.
139. Zambrowicz B., Ding Z.M., Ogbaa I., Frazier K., Banks P., Turnage A., et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013, 3. 273-285e7.
140. Rosenstock J, Zambrowicz B, Lapuerta P, Ogbaa I, Banks P, Freiman J, et al. Impact of LX4211, a dual inhibitor of sodium glucose transporter 1 and 2 on cardiovascular risk factors in type 2 diabetes. Abstract presented at: 2012 American Heart Association annual meeting.
141. LX4211 in subjects with T2DM and renal impairment. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01555008 [accessed 17.01.14].
142. Efficacy and safety of LX4211 in patients with inadequately controlled type 1 diabetes mellitus. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01742208 [accessed 17.01.14].